| scholarly article | Q13442814 |
| P50 | author | Erkki Ruoslahti | Q543772 |
| Namasivayam Ambalavanan | Q38327704 | ||
| P2093 | author name string | Tero A H Järvinen | |
| Takeo Urakami | |||
| Masahiko Oka | |||
| David Mann | |||
| Masanobu Komatsu | |||
| Michie Toba | |||
| Junko Sawada | |||
| Ivan McMurtry | |||
| P2860 | cites work | Inflammation in atherosclerosis | Q29547428 |
| Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF. | Q30974424 | ||
| Vascular zip codes in angiogenesis and metastasis | Q31064524 | ||
| Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle | Q31141702 | ||
| In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging | Q33247563 | ||
| Molecular changes in the vasculature of injured tissues | Q33289271 | ||
| Targeting of drugs and nanoparticles to tumors | Q33751710 | ||
| Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice | Q34411532 | ||
| ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co | Q34971421 | ||
| Inflammation in pulmonary arterial hypertension. | Q35210445 | ||
| Cellular and molecular pathobiology of pulmonary arterial hypertension | Q35803229 | ||
| Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension | Q35833414 | ||
| Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality | Q36120888 | ||
| Pulmonary hypertension: cellular and molecular mechanisms | Q36351090 | ||
| Rat models of cardiovascular diseases | Q37655722 | ||
| Emerging drugs for pulmonary hypertension | Q37679940 | ||
| Endothelial cells in culture: an experimental model for the study of vascular dysfunctions | Q41349204 | ||
| Early inflammatory response during the development of right ventricular heart failure in a rat model | Q43056274 | ||
| Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis | Q44121998 | ||
| Liver inflammation during monocrotaline hepatotoxicity | Q44555107 | ||
| Primary pulmonary hypertension | Q71957743 | ||
| Formation of plexiform lesions in experimental severe pulmonary arterial hypertension | Q84404717 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2489-2495 | |
| P577 | publication date | 2011-05-06 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Peptide-directed highly selective targeting of pulmonary arterial hypertension | |
| P478 | volume | 178 |
| Q41882126 | A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension |
| Q55110701 | Antenatal hypoxia and pulmonary vascular function and remodeling. |
| Q38105550 | Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
| Q92717279 | CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil |
| Q42275475 | Cell permeable peptide conjugated nanoerythrosomes of fasudil prolong pulmonary arterial vasodilation in PAH rats |
| Q48273119 | Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency |
| Q31144876 | Combinatorial peptide libraries: mining for cell-binding peptides |
| Q26772197 | Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition |
| Q38267984 | Endothelial nanomedicine for the treatment of pulmonary disease. |
| Q96124009 | Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa |
| Q51741338 | Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery. |
| Q40854694 | Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs |
| Q88920582 | Generation of a multi-functional, target organ-specific, anti-fibrotic molecule by molecular engineering of the extracellular matrix protein, decorin |
| Q41825036 | II. Capsular vaso-mimicry formed by transgenic mammary tumor spheroids implanted ectopically into mouse dorsal skin fold: implications for cellular mechanisms of metastasis |
| Q38162947 | Inhalation therapy to treat pulmonary arterial hypertension |
| Q39100762 | Lipid-based carriers for controlled delivery of nitric oxide. |
| Q42132055 | Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH. |
| Q89762749 | Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension |
| Q41860260 | Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension |
| Q41890311 | Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension |
| Q37627407 | Peptides as targeting elements and tissue penetration devices for nanoparticles |
| Q44827142 | Recombinant Decorin Fusion Protein Attenuates Murine Abdominal Aortic Aneurysm Formation and Rupture. |
| Q33764713 | Role of epigenetics in pulmonary hypertension |
| Q26782082 | Systemically Administered, Target Organ-Specific Therapies for Regenerative Medicine |
| Q89510783 | Systemically Administered, Target-Specific, Multi-Functional Therapeutic Recombinant Proteins in Regenerative Medicine |
| Q34411532 | Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice |
| Q43198563 | Targeted Antiscarring Therapy for Tissue Injuries |
| Q47675852 | The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). |
Search more.